A Prostacyclin Analog, Cicaprost, Exhibits Potent Anti-Inflammatory Activity in Human Primary Immune Cells and a Uveitis Model

Wang, Jenny W.; Vu, Chau; Poloso, Neil J.

doi:10.1089/jop.2016.0167

Cited by 10 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The fact that steroid or aspirin treatment is not effective in IPAH and HPAH, and that prostacyclin, which has anti-inflammatory properties [57], does not reverse the pulmonary vascular remodelling underscores the fact that additional insights into the roles played by the immune cells and key cytokines/chemokines are a prerequisite for developing novel therapeutic strategies. Recent investigations provide evidence that pulmonary vascular cells are important local sources of soluble signals in PAH that contribute to pulmonary vascular remodelling.…”

Section: Recent Advances In Cellular Abnormalities and Emerging Theramentioning

confidence: 99%

Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives

et al. 2019

View full text Add to dashboard Cite

Clinical and translational research has played a major role in advancing our understanding of pulmonary hypertension (PH), including pulmonary arterial hypertension and other forms of PH with severe vascular remodelling (e.g. chronic thromboembolic PH and pulmonary veno-occlusive disease). However, PH remains an incurable condition with a high mortality rate, underscoring the need for a better transfer of novel scientific knowledge into healthcare interventions. Herein, we review recent findings in pathology (with the questioning of the strict morphological categorisation of various forms of PH into pre- or post-capillary involvement of pulmonary vessels) and cellular mechanisms contributing to the onset and progression of pulmonary vascular remodelling associated with various forms of PH. We also discuss ways to improve management and to support and optimise drug development in this research field.

show abstract

Section: Recent Advances In Cellular Abnormalities and Emerging Theramentioning

confidence: 99%

Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Powerful pro-inflammatory properties and well-studied TLR4-dependent mechanisms of immune system activation resulted in the extensive use of LPS as a model of sepsis and inflammation in mammals [ 60 , 61 ]. Nowadays, advanced medical and veterinary studies utilize more specific in vitro and in vivo models of LPS-induced oxidative stress and inflammation, for example LPS-induced acute lung injury [ 62 ], cardiac dysfunction [ 63 ], periodontitis [ 64 ], acute septic renal injury [ 65 ], uveitis [ 66 ], mastitis [ 67 ], endometritis [ 68 ], preeclampsia [ 69 ], and other. However, there is a particularly wide use of the LPS model in the area of neuroscience research.…”

Section: The Utility Of Lps Inflammation Model In the Research Fieldmentioning

confidence: 99%

Lipopolysaccharide-Induced Model of Neuroinflammation: Mechanisms of Action, Research Application and Future Directions for Its Use

Skrzypczak-Wiercioch

Sałat

2022

Molecules

View full text Add to dashboard Cite

Despite advances in antimicrobial and anti-inflammatory therapies, inflammation and its consequences still remain a significant problem in medicine. Acute inflammatory responses are responsible for directly life-threating conditions such as septic shock; on the other hand, chronic inflammation can cause degeneration of body tissues leading to severe impairment of their function. Neuroinflammation is defined as an inflammatory response in the central nervous system involving microglia, astrocytes, and cytokines including chemokines. It is considered an important cause of neurodegerative diseases, such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Lipopolysaccharide (LPS) is a strong immunogenic particle present in the outer membrane of Gram-negative bacteria. It is a major triggering factor for the inflammatory cascade in response to a Gram-negative bacteria infection. The use of LPS as a strong pro-inflammatory agent is a well-known model of inflammation applied in both in vivo and in vitro studies. This review offers a summary of the pathogenesis associated with LPS exposure, especially in the field of neuroinflammation. Moreover, we analyzed different in vivo LPS models utilized in the area of neuroscience. This paper presents recent knowledge and is focused on new insights in the LPS experimental model.

show abstract

“…Consistently, altered regulatory T-cell function [66,67], T-helper 17 cell immune polarisation [68], dendritic cell recruitment in pulmonary vascular lesions [69] and the presence of lymphoid neogenesis in lungs have been demonstrated in patients with PAH [70,71]. However, the fact that steroid or aspirin treatment are clearly not effective in idiopathic and heritable PAH [72], and that prostacyclin, which has anti-inflammatory properties [73][74][75], does not reverse the pulmonary vascular remodelling and PAH, support the need for a better characterisation of the involvement and mechanism of distinct immune cells and key inflammatory mediators. This better knowledge could pave the way to novel therapeutic strategies for predefined groups of patients and could help to identify panels of key inflammatory mediators to distinguish different PH/PAH clinical phenotypes.…”

Section: Is Precision Medicine Ready For Use In Pah/ph?mentioning

confidence: 90%

Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era

et al. 2018

View full text Add to dashboard Cite

Pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) include different cardiopulmonary disorders in which the interaction of multiple genes with environmental and behavioural factors modulates the onset and the progression of these severe conditions. Although the development of therapeutic agents that modulate abnormalities in three major pathobiological pathways for PAH has revolutionised our approach to the treatment of PAH, the long-term survival rate remains unsatisfactory. Accumulating evidence has underlined that clinical outcomes and responses to therapy in PAH are modified by multiple factors, including genetic variations, which will be different for each individual. Since precision medicine, also known as stratified medicine or personalised medicine, aims to better target intervention to the individual while maximising benefit and minimising harm, it has significant potential advantages. This article aims to assemble and discuss the different initiatives that are currently underway in the PH/PAH fields together with the opportunities and prospects for their use in the near future.

show abstract

A Prostacyclin Analog, Cicaprost, Exhibits Potent Anti-Inflammatory Activity in Human Primary Immune Cells and a Uveitis Model

Cited by 10 publications

References 27 publications

Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives

Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives

Lipopolysaccharide-Induced Model of Neuroinflammation: Mechanisms of Action, Research Application and Future Directions for Its Use

Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era

Contact Info

Product

Resources

About